X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2163) 2163
Publication (253) 253
Book Review (38) 38
Book Chapter (20) 20
Dissertation (3) 3
Conference Proceeding (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1345) 1345
index medicus (1009) 1009
oncology (993) 993
hematology (867) 867
female (792) 792
male (735) 735
middle aged (624) 624
adult (575) 575
aged (509) 509
relapsed (502) 502
chemotherapy (497) 497
treatment outcome (412) 412
antineoplastic combined chemotherapy protocols - therapeutic use (399) 399
recurrence (393) 393
cancer (390) 390
therapy (329) 329
refractory (325) 325
multiple myeloma (324) 324
transplantation (293) 293
bortezomib (269) 269
care and treatment (254) 254
adolescent (239) 239
antineoplastic agents - therapeutic use (239) 239
multiple myeloma - drug therapy (214) 214
salvage therapy (200) 200
disease-free survival (197) 197
stem-cell transplantation (196) 196
dexamethasone (190) 190
aged, 80 and over (188) 188
phase-ii (184) 184
relapse (184) 184
relapsed multiple-myeloma (184) 184
antineoplastic combined chemotherapy protocols - adverse effects (181) 181
survival (177) 177
medicine & public health (176) 176
retrospective studies (174) 174
lenalidomide (172) 172
prognosis (171) 171
immunotherapy (167) 167
pharmacology & pharmacy (164) 164
bone-marrow-transplantation (162) 162
leukemia (160) 160
child (158) 158
lymphomas (158) 158
rituximab (158) 158
research (154) 154
immunology (151) 151
stem cells (149) 149
remission induction (147) 147
trial (144) 144
hematopoietic stem cell transplantation (143) 143
diseases (136) 136
antineoplastic combined chemotherapy protocols - administration & dosage (134) 134
hematology, oncology and palliative medicine (134) 134
young adult (134) 134
combination (133) 133
neoplasm recurrence, local - drug therapy (133) 133
patients (133) 133
survival rate (132) 132
relapsed leukemia (129) 129
survival analysis (129) 129
animals (127) 127
article (127) 127
drug administration schedule (126) 126
child, preschool (125) 125
drug resistance, neoplasm (123) 123
acute myeloid-leukemia (120) 120
analysis (119) 119
drug therapy (119) 119
health aspects (119) 119
clinical trials (117) 117
combined modality therapy (116) 116
transplantation, homologous (116) 116
non-hodgkins-lymphoma (115) 115
cyclophosphamide (113) 113
relapsed/refractory (113) 113
children (111) 111
antineoplastic agents - adverse effects (108) 108
lymphoma (107) 107
pediatrics (107) 107
stem cell transplantation (106) 106
thalidomide - analogs & derivatives (101) 101
etoposide (100) 100
acute myelogenous leukemia (97) 97
follow-up studies (96) 96
high-dose chemotherapy (96) 96
toxicity (93) 93
dexamethasone - administration & dosage (92) 92
hematopoietic stem cells (91) 91
thalidomide (91) 91
bone-marrow transplantation (89) 89
antineoplastic agents - administration & dosage (88) 88
phase-ii trial (88) 88
clinical trials as topic (87) 87
leukemia, myeloid, acute - drug therapy (87) 87
disease (86) 86
hemic and lymphatic diseases (85) 85
transplantation, autologous (85) 85
open-label (84) 84
acute lymphoblastic-leukemia (83) 83
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2095) 2095
German (16) 16
Japanese (14) 14
Dutch (11) 11
French (11) 11
Spanish (8) 8
Korean (5) 5
Polish (5) 5
Russian (5) 5
Turkish (5) 5
Chinese (3) 3
Czech (3) 3
Portuguese (3) 3
Italian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1932 - 1938
Abstract Background Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic... 
relapsed/refractory NHL | phase Ib | venetoclax | bendamustine-rituximab | relapsed | refractory NHL | Original | bendamustine–rituximab
Journal Article
The Oncologist, ISSN 1083-7159, 11/2019, Volume 24, Issue 11, pp. 1479 - 1487
Background Therapy choices in relapsed/refractory multiple myeloma (RRMM) should consider patient satisfaction with treatment, because it is associated with... 
Relapsed/refractory multiple myeloma | Treatment satisfaction | Time burden | Indirect treatment costs | refractory multiple myeloma | Relapsed | Hematologic Malignancies
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 02/2019, Volume 60, Issue 3, pp. 610 - 618
Ixazomib, as a proteasome inhibitor, inhibits the chymotrypsin-like activity of the β5 subunit of the 20S proteasome. Based on the TOURMALINE-MM1 study,... 
relapsed/refractory multiple myeloma | Ixazomib | proteasome inhibitor | MLN9708 | METAANALYSIS | EFFICACY | SAFETY | refractory multiple myeloma | THALIDOMIDE | COMBINATION | RELAPSED/REFRACTORY MULTIPLE-MYELOMA | PLUS LENALIDOMIDE-DEXAMETHASONE | PHARMACOKINETICS | ONCOLOGY | PHASE-1 | relapsed | HEMATOLOGY
Journal Article
Leukemia Research, ISSN 0145-2126, 09/2019, Volume 84, p. 106188
Salvage regimens in relapsed/refractory Hodgkin’s lymphoma (HL) differ in their efficacy and toxicity profiles. Gemcitabine (G), vinorelbine (V) and liposomal... 
Adults | Salvage | Relapsed | Paediatrics | Hodgkin’s lymphoma
Journal Article
Oncotarget, ISSN 1949-2553, 01/2019, Volume 10, Issue 2, pp. 82 - 83
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2019, Volume 185, Issue 3, pp. 623 - 627
Table SVI. Bioavailability and Safety of Midostaurin Oral Solution and Capsule Formulations in Healthy Volunteers in Study A2108 
relapsed/refractory | midostaurin | acute leukaemia | FLT3 | paediatric | refractory | INHIBITION | relapsed | PROGNOSTIC-SIGNIFICANCE | MLL | HEMATOLOGY | EXPRESSION | Relapse | Oral medication | Analysis | Diseases | Refractory materials | Leukemia | Children
Journal Article
Journal Article
Journal of Pediatric Hematology/Oncology, ISSN 1077-4114, 2018, p. 1
Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90% tumor necrosis have all been known to influence... 
relapsed | pediatric osteosarcoma | pazopanib | MAP | oncology
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 2016, Volume 27, Issue 12, pp. 2251 - 2257
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S24 - S27
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 05/2019, Volume 35, Issue 5, pp. 927 - 935
Objective: The aim of this analysis was to examine treatment patterns in patients with acute myeloid leukemia (AML) in routine clinical practice in the United... 
Adelphi Programme | real-world study | relapsed/refractory | treatment intensity | Acute myeloid leukemia | MEDICINE, RESEARCH & EXPERIMENTAL | refractory | MEDICINE, GENERAL & INTERNAL | CLINICAL-TRIALS | relapsed | OUTCOMES
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 07/2019, Volume 60, Issue 9, pp. 2143 - 2151
In preclinical studies, oral azacitidine (CC-486), a hypomethylating agent, has been shown to have a direct anti-MM effect and in vitro anti-MM synergism when... 
cereblon | lenalidomide | proteomics | Relapsed/refractory myeloma | oral azacitidine | DARATUMUMAB | SURVIVAL | HYPERMETHYLATION | EFFICACY | 5-AZACYTIDINE | SAFETY | Relapsed | CEREBLON EXPRESSION | POMALIDOMIDE | refractory myeloma | CARFILZOMIB | ONCOLOGY | HEMATOLOGY | LOW-DOSE DEXAMETHASONE
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 04/2019, Volume 19, Issue 4, pp. e195 - e203
The combination of lenalidomide and dexamethasone (Len-Dex) is an established regimen for patients with relapsed or refractory myeloma. To prolong the benefit... 
Refractory | Cyclophosphamide | Lenalidomide | Relapsed | Multiple myeloma
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2018, Volume 82, Issue 3, pp. 511 - 519
Patients with RAS-positive tumors respond poorly to chemotherapies and have a few treatment options. Salirasib is an oral RAS inhibitor that competitively... 
KRAS mutation | Medicine & Public Health | Salirasib | Phase I clinical trial | Oncology | Cancer Research | S - trans | Trans -farnesylthiosalicylic acid | Relapsed/refractory solid tumors | Pharmacology/Toxicology | S-trans | Trans-farnesylthiosalicylic acid | NUDE-MICE | Relapsed/ refractory solid tumors | N-RAS | PANCREATIC-CANCER | METASTATIC COLORECTAL-CANCER | PANITUMUMAB | ONCOLOGY | GROWTH | LUNG ADENOCARCINOMA | PHARMACOLOGY & PHARMACY | KRAS | FARNESYLTHIOSALICYLIC ACID | Neoplasms - metabolism | Salicylates - pharmacokinetics | Humans | Middle Aged | Farnesol - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Enzyme Inhibitors - adverse effects | Farnesol - adverse effects | Farnesol - pharmacokinetics | Salicylates - administration & dosage | ras Proteins - antagonists & inhibitors | Salicylates - adverse effects | Neoplasms - drug therapy | Farnesol - analogs & derivatives | Aged | Neoplasm Staging | Neoplasms - pathology | Proteins | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Cancer | Tumors | Dosing | Toxicity | Diarrhea | Nausea | Pharmacology | Patients | K-Ras protein | Pain | Inhibitors | Mutation | Solid tumors | Pharmacokinetics | Relapsed | refractory solid tumors | Original
Journal Article
Blood reviews, ISSN 0268-960X, 08/2019, p. 100616
The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.